Navigation Links
NxStage Celebrates Seven Year Anniversary of IU Health's Home Hemodialysis Program and Patient Milestones
Date:8/15/2011

LAWRENCE, Mass., Aug. 15, 2011 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, is celebrating Indiana University Health's (IU Health) seventh anniversary of its program to offer home hemodialysis to patients with the NxStage System One™.  IU Health started its home dialysis program by partnering with NxStage on its Investigational Device Exemption (IDE) study for U.S. Food and Drug Administration (FDA) clearance to market the System One for home use. In addition, three IU Health patients who were among the first ever to receive dialysis with the System One, are celebrating more than seven years with the therapy.

(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO)

Long-time dialysis patient Rick Skiles, 57, had tried numerous treatment modalities when he learned about NxStage's clinical trial study at IU Health in 2004. Skiles enrolled and became the first patient in Indiana to train on the NxStage System One. More than seven years later, the flexibility to do his treatments on his own time and the health benefits he has realized thanks to more frequent treatments have helped Skiles lead a liberated, healthy life. "I feel extremely fortunate as a patient at IU Health to have had the opportunity to be among the first daily home hemodialysis patients," says Skiles. "With the System One, I felt I got my life back, and I look forward to many active, healthy years to come with this therapy."

"We applaud healthcare providers and partners such as IU Health for helping to pioneer daily home hemodialysis with the NxStage System One," said Jeffrey H. Burbank, Chief Executive Officer of NxStage Medical. "Because of their leadership, enthusiasm, and continued commitment to advancing renal care, a growing number of dialysis patients like Rick are realizing the life-changing benefits possible with daily home hemodialysis."

NxStage and IU Health will host an educational event on Wednesday, August 17, 2011 at University Place Conference Center in Indianapolis to bring together the IU home dialysis patients, including Rick Skiles, and their care partners.

About NxStage

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the company's website at www.nxstage.com.

About Indiana University Health

Named among the "Best Hospitals in America" by U.S. News Media & World Report for 14 consecutive years, Indiana University Health is dedicated to providing a unified standard of preeminent, patient-centered care. A unique partnership with Indiana University School of Medicine - one of the nation's leading medical schools - gives our highly skilled physicians access to innovative treatments using the latest research and technology. Discover the strength at iuhealth.org.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors that are discussed in NxStage's Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 filed with the SEC. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contacts:
Kristen Sheppard, Esq.
Vice President, Investor Relations
NxStage Medical, Inc.
ir@nxstage.com
978-332-5923


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NxStage(R) to Recognize Several Key Milestones at American Society of Nephrologys Renal Week 2007
2. Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts
3. NxStage(R) to Report Third Quarter 2009 Financial Results
4. NxStage(R) Reports Significant Interim FREEDOM Study Results
5. NxStage(R) and Nordic Medcom Sign Distribution Agreement for the System One(TM)
6. NxStage(R) Reports Third Quarter 2009 Financial Results and Raises Revenue Guidance for Fiscal 2009
7. Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM)
8. NxStage(R) Secures $15 Million Revolving Line of Credit
9. NxStage to Report Third Quarter Fiscal 2010 Financial Results
10. NxStage® Expands Product Portfolio With Innovative Patient Access Surveillance Solution From Vasc-Alert™
11. NxStage Announces Fourth Quarter 2010 Investor Conference Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec. 2, 2016 The U.S. Food ... Jardiance (empagliflozin) to reduce the risk of cardiovascular death ... cardiovascular disease. "Cardiovascular disease is a ... diabetes mellitus," said Jean-Marc Guettier , M.D., C.M., ... in FDA,s Center for Drug Evaluation and Research. "Availability ...
(Date:12/2/2016)... 2, 2016 Persistence Market Research ... its upcoming report titled, "Global Market Study on Cardiac Pacemaker: ... of -1.4% between 2016 and 2024". The global cardiac pacemaker ... and this is likely to decline to US$ 3923.8 ... cardiac pacemaker market is anticipated to exhibit a declining ...
(Date:12/2/2016)... NEW YORK , December 2, 2016 ... Market Research titled "Global Market Study on Automated Endoscope Reprocessors: ... Register a CAGR of 8.6% Between 2016 and 2024 " the ... 2015 and is expected to expand at a CAGR of ... market valuation of US$ 1,367.6 Mn by 2024. ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma ... innovative lymphoma research and serving the lymphoma community through a comprehensive series of ... Wine Tasting Event in New York City, with long-time partners The Paul Foundation, ...
(Date:12/4/2016)... ... December 04, 2016 , ... "Pro3rd Displace is ... styles with unique displacement design elements," said Christina Austin - CEO of Pixel ... from a variety of design styles that include both left aligned and right ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and ... will speak at the American Conference Institute’s 21st Drug & Medical Device Litigation ... Lead Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Advanced Inc., a ... has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, ... Inc. , Jason brings extensive financial and operational leadership experience to Advanced Inc. ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... With ... struggling through rehabilitation of an injury, patients must find the one that works for ... his pain, he created a machine that worked and decided to share it with ...
Breaking Medicine News(10 mins):